Biologics (Jan 2024)

Respiratory Syncytial Virus Vaccines for the Prevention of Lower Respiratory Tract Infections in Patients Living with Chronic Obstructive Pulmonary Disease: A Rapid Review

  • Paul M. Boylan,
  • Megan E. Fleischman,
  • Nathan Pinner,
  • Joseph Andrew Woods,
  • Adam Welch

DOI
https://doi.org/10.3390/biologics4010002
Journal volume & issue
Vol. 4, no. 1
pp. 17 – 29

Abstract

Read online

Background: Patients living with chronic obstructive pulmonary disease (COPD) are at risk for lower respiratory tract infections caused by respiratory syncytial virus (RSV). The first RSV vaccines were approved in 2023 for adults ages 60 years and older. The safety and efficacy of the RSV vaccines and their clinical implications in patients living with COPD, apart from composite comorbidity results, are under-reported. Methods: This rapid review aimed to collect and report data pertaining to RSV vaccine safety and efficacy in patients living with COPD. Resources searched included Ovid MEDLINE, EMBASE, International Pharmaceutical Abstracts, published peer-reviewed abstracts, ClinicalTrials.gov, and the United States Food and Drug Administration (FDA) website. Results: Seven records were included: five research manuscripts and two ongoing clinical trials. Patients living with COPD were included in RSV vaccine clinical trials, but outcomes of RSV vaccine safety and efficacy in patients living with COPD were grossly unreported. Conclusions: Future clinical trials of patients living with COPD and subgroup analyses of patients living with COPD within existing studies evaluating RSV vaccine safety and efficacy are necessary to substantiate outcomes in this population.

Keywords